coronary artery disease/protease

Bağlantı panoya kaydedilir

Sıralama türünü seçin

Sayfa 1 itibaren 351 Sonuçlar

Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND Thrombin receptor antagonists blocking protease-activated receptor-1 (PAR-1) on platelets represent a new class of oral antiplatelet agents for patients with atherothrombotic disease manifestations. OBJECTIVE We investigated the safety and efficacy of PAR-1 antagonists in patients with

The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

E5555 is a potent protease-activated receptor (PAR-1) antagonist targeting the G-coupled receptor and modulating thrombin-platelet-endothelial interactions. The drug is currently being tested in phase II trials in patients with coronary artery disease (CAD) and has potential antithrombotic and

Expression of the Marburg I Single Nucleotide Polymorphism (MI-SNP) and the Marburg II Single Nucleotide Polymorphism (MII-SNP) of the Factor VII-Activating Protease (FSAP) Gene and Risk of Coronary Artery Disease (CAD): A Pilot Study in a Single Population.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND Factor VII-activating protease (FSAP) has a role in vascular inflammation and may have a role coronary artery disease (CAD). The aim of this study was to investigate the association between two naturally occurring single nucleotide polymorphisms (SNPs) in the FSAP gene and the risk of

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

There is continued concern about protease inhibitors (PIs) causing increased risk of coronary heart disease (CHD) in HIV-infected patients. This ongoing observational study examines CHD and myocardial infarction (MI) hospitalization rates among HIV-positive members of the Kaiser Permanente Medical

Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Four cases of human immunodeficiency virus (HIV)-infected patients who developed coronary heart disease (CHD) while under treatment with a protease inhibitor (PI) are described, and the epidemiologic and clinical features of 18 cases reported in the literature are analyzed. Cardiac manifestations

Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

The haemostatic activity of von Willebrand Factor (VWF) is dependent on VWF multimer stability. Fragments, arising from the proteolytic cleavage of the multimers by VWF-cleaving protease, are ineffective in initiating platelet aggregation. We designed a simple method to determine the protease

Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Low levels of von Willebrand factor (VWF) in von Willebrand's disease type 2A (VWD 2A) result from increased cleavage of the bond 842Tyr-843Met in the VWF protein by VWF cleaving protease. On the other hand, decreased levels of this protease result in unusually large VWF in thrombotic

Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

High plasma level of von Willebrand factor (VWF) is a marker of future cardiovascular events in patients at high risk of coronary artery disease (CAD). The purpose of this study was to examine the changes and the prognostic value of plasma VWF-cleaving protease (ADAMTS13) levels in patients with

A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

OBJECTIVE The purpose of this study was to identify genetic variants associated with severe coronary artery disease (CAD). RESULTS We used 3 case-control studies of white subjects whose severity of CAD was assessed by angiography. The first 2 studies were used to generate hypotheses that were then

PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Objective: Arterial thrombosis leading to ischemic injury worsens the prognosis of many patients with cardiovascular disease. PZ-128 is a first-in-class pepducin that reversibly inhibits PAR1 (protease-activated receptor 1) on platelets

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

OBJECTIVE Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary

HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Differences on measures of metabolic syndrome X and coronary heart disease (CHD) risk, as well as potential pathophysiological mediators, inflammation, and oxidative stress, were examined as a function of HIV serostatus and highly active antiretroviral therapy (HAART) regimen with and without

Protease variants, LDL, and coronary heart disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

A comparison of different protease inhibitors on coronary heart disease risk.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Left main coronary artery disease in a 40-year-old man receiving HIV protease inhibitors.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Facebook sayfamıza katılın

Herbal & Natural Medicine

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

55 dilde çalışır
Bilim destekli bitkisel kürler
Görüntüye göre bitki tanıma
Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
Aramanızla ilgili bilimsel yayınları okuyun
Şifalı bitkileri etkilerine göre arayın
İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır